← Leaderboards
Dinesh Khanna
University Of California Los Angeles
$4,798,098
Attributed
$7,168,336
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $876.2K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,168,336 · 9
By mechanism
U01$2,214,728 · 1
R01$1,827,499 · 2
K24$1,561,750 · 1
K23$616,950 · 1
UM1$546,000 · 1
R34$374,431 · 1
Top collaborators
- Brennan Spiegel7 shared
- David Alan Fox5 shared
- Johann Eli Gudjonsson2 shared
- Susan L Murphy2 shared
- Pei-Suen Tsou2 shared
- Peter A Merkel1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Peter M Bentler$7,293,491
- Elizabeth R Volkmann$1,603,888
- Donald P Tashkin$15,930,292
- Sean Young$19,183,048
- Connie L Kasari$33,208,285
Others in their field
Top investigators on “Systemic Scleroderma”
- Eugene W. St Clair · Duke University$24,182,181
- John Varga · University Of Illinois At Chicago$13,781,985
- Carol A Feghali-Bostwick · University Of Pittsburgh At Pittsburgh$11,771,501
- Judith A James · Oklahoma Medical Research Foundation$11,331,322
- Robert M Elashoff · John Wayne Cancer Institute$10,394,671
- Maria Trojanowska · Boston University Medical Campus$10,085,547
Research focus
Systemic SclerodermaSclerodermaResearch PersonnelUniversitiesClinical ResearchProgramsClinical TrialsFutureResponseSkinReportingCutaneousClinical Trials DesignFundingPatient Outcomes AssessmentsInterviewCharacteristicsTrainingMichiganValidationPathogenesisRheumatismInformation SystemsMeasurement
Grant awards (36)
Role of the Hippo pathway in scleroderma pathogenesis$583,594
R01 · FY2025 · AI
Planning for a Multisite Efficacy Trial of Upper Extremity Telerehabilitation for Systemic Sclerosis$99,871
R34 · FY2025 · AR
Role of the Hippo pathway in scleroderma pathogenesis$601,644
R01 · FY2024 · AI
Planning for a Multisite Efficacy Trial of Upper Extremity Telerehabilitation for Systemic Sclerosis$274,560
R34 · FY2024 · AR
University of Michigan Clinical Autoimmunity Center of Excellence$78,000
UM1 · FY2023 · AI · contact PI
Outcomes Research in Rheumatic Diseases$132,764
K24 · FY2022 · AR · contact PI
University of Michigan Clinical Autoimmunity Center of Excellence$78,000
UM1 · FY2022 · AI · contact PI
Outcomes Research in Rheumatic Diseases$132,764
K24 · FY2021 · AR · contact PI
University of Michigan Clinical Autoimmunity Center of Excellence$78,000
UM1 · FY2021 · AI · contact PI
Outcomes Research in Rheumatic Diseases$132,764
K24 · FY2020 · AR · contact PI
University of Michigan Clinical Autoimmunity Center of Excellence$78,000
UM1 · FY2020 · AI · contact PI
Systemic Sclerosis-Associated Interstitial Lung Disease Response Index$273,943
R01 · FY2019 · AR · contact PI
University of Michigan Clinical Autoimmunity Center of Excellence$234,000
UM1 · FY2019 · AI · contact PI
Outcomes Research in Rheumatic Diseases$132,764
K24 · FY2019 · AR · contact PI
Developing a White Paper on Trial Design in Systemic Sclerosis: A Consensus Meeting of Stakeholders in Scleroderma$25,000
R13 · FY2019 · AR · contact PI
Systemic Sclerosis-Associated Interstitial Lung Disease Response Index$251,943
R01 · FY2018 · AR · contact PI
Outcomes Research in Rheumatic Diseases$132,764
K24 · FY2018 · AR · contact PI
Systemic Sclerosis-Associated Interstitial Lung Disease Response Index$116,375
R01 · FY2017 · AR · contact PI
Outcomes Research in Rheumatic Diseases$179,586
K24 · FY2016 · AR · contact PI
Outcomes Research in Rheumatic Diseases$179,586
K24 · FY2015 · AR · contact PI
Outcomes Research in Rheumatic Diseases$179,586
K24 · FY2014 · AR · contact PI
Development and Initial Validation of PROMIS GI Distress Scale$200,000
U01 · FY2013 · AR
Outcomes Research in Rheumatic Diseases$179,586
K24 · FY2013 · AR · contact PI
Development and Initial Validation of PROMIS GI Distress Scale$30,000
U01 · FY2013 · AR
Development and Initial Validation of PROMIS GI Distress Scale$293,398
U01 · FY2012 · AR
Development and Initial Validation of PROMIS GI Distress Scale$191,835
U01 · FY2012 · AR
Outcomes research in rheumatic diseases$179,586
K24 · FY2012 · AR · contact PI
Development and Initial Validation of PROMIS GI Distress Scale$485,233
U01 · FY2011 · AR
Health Values and Minimally Important Differences in Systemic Sclerosis$123,390
K23 · FY2011 · AR · contact PI
Development and Initial Validation of PROMIS GI Distress Scale$503,706
U01 · FY2010 · AR · contact PI
Health Values and Minimally Important Differences in Systemic Sclerosis$123,390
K23 · FY2010 · AR · contact PI
CURCUMIN IN RHEUMATOID ARTHRITIS A CROSS-OVER PILOT STUDY$1,978
M01 · FY2010 · RR · contact PI
Development and Initial Validation of PROMIS GI Distress Scale$510,556
U01 · FY2009 · AR · contact PI
Health Values and Minimally Important Differences in Systemic Sclerosis$123,390
K23 · FY2009 · AR · contact PI
Health Values and Minimally Important Differences in Systemic Sclerosis$123,390
K23 · FY2008 · AR · contact PI
Health Values and Minimally Important Differences in Systemic Sclerosis$123,390
K23 · FY2007 · AR · contact PI